JBIO (Jade Biosciences) Total Assets: $319.43 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JBIO Jade Biosciences Inc JBIO
12 GF Score
Price $20.85
! 1 Warning Sign
View Full Analysis

What is Jade Biosciences Total Assets?

Jade Biosciences JBIO +1.88% 12 Total Assets is $319.43 Mil as of Mar. 2026. GuruFocus rates JBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Jade Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $319.43 Mil.

During the past 12 months, Jade Biosciences's average Total Assets Growth Rate was 299.20% per year.

Total Assets is connected with ROA %. Jade Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -48.26%. Total Assets is also linked to Revenue through Asset Turnover. Jade Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Jade Biosciences  (NAS:JBIO) Total Assets Explanation

Total Assets is connected with ROA %.

Jade Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-161.472/( (349.781+319.433)/ 2 )
=-161.472/334.607
=-48.26 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Jade Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (349.781+319.433)/ 2 )
=0/334.607
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Jade Biosciences Total Assets Related Terms

Jade Biosciences Total Assets Historical Data

* Premium members only.

The historical data trend for Jade Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jade Biosciences Total Assets Chart

Jade Biosciences Annual Data
Trend Dec24 Dec25
Total Assets
72.80 349.78

Jade Biosciences Quarterly Data
Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial 0.00 223.97 202.45 349.78 319.43
JBIO
12GF Score
Jade Biosciences Inc JBIO
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jade Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Jade Biosciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=332.518+17.263
=349.78

Jade Biosciences's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=296.462+22.971
=319.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $319.43 Mil mean?
Jade Biosciences (JBIO) has a Total Assets of $319.43 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Jade Biosciences and its competitors.
Is Jade Biosciences' Total Assets too high?
Jade Biosciences' current Total Assets is $319.43 Mil. Overall, Jade Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Jade Biosciences' Total Assets compare to AVLN and ARDX?
Jade Biosciences' Total Assets of $319.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Jade Biosciences and its competitors. Jade Biosciences's current Total Assets is $319.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jade Biosciences stock overvalued right now?
Jade Biosciences (JBIO) has a current Total Assets of $319.43 Mil. The current Total Assets is $319.43 Mil. Jade Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Jade Biosciences (JBIO), the current Total Assets is $319.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jade Biosciences Business Description

Address 221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02453
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
12GF Score

Get the complete analysis for JBIO

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.85
Price